Business Wire

WA-PATTERN-COMPUTER

17.6.2021 22:05:07 CEST | Business Wire | Press release

Share
Pattern Computer Develops Accurate 15-Second COVID-19 Test

Pattern Computer,® Inc . (PCI) has developed a novel test for near real-time (15 sec) diagnosis of SARS-CoV-2 infections. In contrast with widely used antibody and PCR tests, which take at least 15 minutes to produce results, and require scarce reagents to process, the newly developed PCI method enables high-volume throughput of tests without requiring chemical reagents at difficult to service locations, such as company entrances, event venues, court houses, state and federal facilities, TSA screening areas and ports of entry.

“Having a simple, fast, easy to administer, high accuracy COVID-19 test will be critical for TSA and the airline carriers to increase passenger safety and confidence, as carriers deal with rising passenger loads and increased health security requirements,” said Bob Edwards, former CIO for United Airlines. “Pattern Computer’s new system appears to meet that need.”

Developed using the Pattern Discovery Engine™ (PDE) comprised of proprietary software methods and specially configured hardware, the initial results suggest this low-cost, high-volume COVID-19 test could create new opportunities for reducing transmission risk in high-headcount, high-density entertainment venues, large-scale events, office buildings, trains, busses, aircraft, and subways.

“As the world enters the next cycles of COVID lockdowns and flareups, there will be a pressing need for the companion technology to vaccines – the ability to detect true positive infections, and simultaneously reduce the incidence of false positives, coupled with higher reliability rates, delivered in real time. These are the required characteristics of a regimen of testing that will enable better containment of future outbreaks. The Pattern Computer team was able to apply the proven abilities of the Pattern Discovery Engine to take on this daunting challenge. We wanted to create a high-performance, extremely accurate, reagent-free, real-time alternative for testing in the world’s most important venues. This combination of proprietary hardware and software appears capable of meeting that critical need,” according to Mark R. Anderson, CEO of Pattern Computer.

Pattern Computer’s new test has been used to analyze data from symptomatic and asymptomatic patients between 10 and 80 years old. The reported balanced accuracy of the new test is >96%. The aspects of the testing that are worth noting: the Pattern team has been working on the problem for a few months, and is working with a dataset that numbers in the hundreds of data points. Competing organizations and teams have been working on the same problem for over a year with millions of data points, to only deliver tests that are 97% accurate.

The results from the Pattern tests are competitive with the performance of antibody tests currently in the market, which under ideal conditions (3 weeks after onset of symptoms) reports a balanced accuracy of 95%1 . In contrast to antibody tests, which are highly sensitive to timing--only 30% of people infected with SARS-CoV-2 tests positive 1 week after the onset of symptoms--the performance of PCI diagnosis is agnostic regarding how long the patient has been symptomatic.

“Pattern Computer has rapidly developed a reagent free SARS-CoV-2 diagnostic platform with an impressive level of accuracy. This technology has the potential to alter the landscape of disease diagnostics. Currently, they are focused on COVID-19, but their approach is applicable, in principle, to any disease. I suspect that, in the new future, as we walk through TSA security at an airport, part of the screen will be for infectious diseases. The implications of this technology for public safety and health, especially disease surveillance, are enormous,” said Prof. J. Ben Brown, UC Berkeley & Lawrence Berkeley National Laboratory.

PCI has built an initial model that predicts COVID-19 status (as determined by multi-target RT-PCR) of a patient based on its proprietary hardware measurements. Sensitivity and specificity are computed with 5-fold cross-validation.

PCI expects that as more data points are added to the PCI data base, particularly data from non-infected individuals, its technology will be able to match or exceed RT-PCR for accurate SARS-CoV-2 infection detection, with the reduced result time of 20 seconds rather than the current standard wait time of 30 minutes or more2 .

The foregoing contains statements about the Pattern Computer’s future that are not statements of historical fact. These statements are “forward-looking statements” for purposes of applicable securities laws and are based on current information and/or management's good faith belief as to future events. The words “believe,” “expect,” “anticipate,” “project,” “should,” “could,” “will,” and similar expressions signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance. By their nature, forward-looking statements involve inherent risk and uncertainties, which change over time, and actual performance could differ materially from that anticipated by any forward-looking statements. Pattern Computer undertakes no obligation to update or revise any forward-looking statement.

About Pattern Computer

Pattern Computer, Inc., a Seattle-area startup, uses its proprietary Pattern Discovery Engine to solve the most important and most intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems.

While the company is currently applying its computational platform to the challenging field of drug discovery, it is also making pattern discoveries for partners in several other sectors, including additional biomedical research, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and finance.

For more information on Pattern Computer Inc., visit: www.patterncomputer.com

For more information about Mark Anderson, visit: www.patterncomputer.com/founders/

Copyright © 2021 Pattern Computer, Inc. All Rights Reserved. Pattern Computer Inc., and PCI are trademarks of Pattern Computer, Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.

_________________________________________________

1 Antibody tests for identification of current and past infection with SARS‐CoV‐2 - Deeks, JJ - 2020 | Cochrane Library , https://doi.org/10.1002/14651858.CD013652 , June 25, 2020
2 Covid-19: Bosch develops “fastest” PCR test in the world (msn.com) , https://www.msn.com/en-ae/news/other/covid-19-bosch-develops-fastest-pcr-test-in-the-world/ar-BB1aNLVB , August 11, 2020

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

GenBio AI Builds First World Model of the Human Cell18.8.2026 15:00:00 CEST | Press release

First-of-its-kind system simulates human cell behavior across the full biological hierarchy, from DNA and RNA through protein to the whole-cell level GenBio AI ('GenBio') is an AI for Science company co-founded by Nobel Laureate David Baker, leading AI scientist Eric Xing, and other prominent life science and artificial intelligence researchers from Stanford, Carnegie Mellon University, Mohamed Bin Zayed University of Artificial Intelligence, Harvard, Weizmann Institute, and other research institutions. Today, the company introduced AIDO Cell, its virtual cell world model — the first system capable of simulating a human cell, both in its natural state and in response to drugs and other interventions, across its full biological hierarchy, from DNA and RNA through protein to the whole-cell level. A Key First in Biological and Medical Sciences: Full-hierarchy virtual cell simulation has been widely identified as a key milestone in computational biology. Compared to the previous efforts by

Xsolla Partner Network Expands Verified Creator Partnerships and Unifies Campaign Management Ahead of gamescom 202618.8.2026 15:00:00 CEST | Press release

Developers Gain Vetted Creator Partnerships And A Single Campaign Workflow, Managed From The Publisher Account They Already Use Xsolla, a global video game commerce company, today announced an expansion of the Xsolla Partner Network ahead of gamescom 2026 in Cologne, giving game developers a simpler, more reliable way to grow their games through creators. The creator platform now lives within Xsolla Publisher Account, where developers already run their business, with verified creator onboarding and a redesigned and unified campaign workflow. Flat-fee campaigns, a new guaranteed payment option alongside revenue share, and data-driven creator recommendations are coming soon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818140062/en/ Graphic: Xsolla Xsolla Partner Network gives developers one place to launch, manage, track, and report on creator campaigns while Xsolla handles payments, payouts, taxes, and compliance.Verifi

KOCCA to Showcase 13 Korean Game Companies at ‘Gamescom 2026’ with PC, Mobile, and VR Lineups18.8.2026 14:48:00 CEST | Press release

- Featuring a diverse lineup of roguelike deckbuilders, AI-powered rhythm education, and cooperative horror games - Ranging from new titles based on the popular animated IP ‘LARVA’ to real-time K-POP dance coaching content - Hands-on experience available August 26–28 at the Korea Joint Pavilion B2B Hall, Koelnmesse, Booth Hall 3.2 C-050g–D051g The Korea Creative Content Agency (KOCCA) announced that 13 Korean game companies will gather under one roof at Gamescom 2026, Europe’s largest game show, held in Cologne, Germany, from August 26 to 28 (B2B, 09:00~20:00). Located in Booth Hall 3.2 C-050g–D051g, the Korea Joint Pavilion offers visitors hands-on experiences with an expansive lineup of titles, ranging from PC and mobile games to VR-powered titles across diverse genres. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818271881/en/ KOCCA will bring 13 Korean game companies to Gamescom 2026 in Cologne, Germany (Image: KOCC

SLB to Support Offshore Production Restoration for Brunei Shell Petroleum18.8.2026 14:06:00 CEST | Press release

Integrated execution model combines multiple disciplines to improve recovery from mature offshore assets Global energy technology company SLB (NYSE: SLB) today announced it has been awarded a contract by Brunei Shell Petroleum (BSP) to support production restoration from shut-in wells across multiple offshore fields. The contract scope spans subsurface evaluation, well candidate selection, engineering and offshore execution. Project management, intervention services, monitoring, metering and marine logistics are integrated within a single coordinated execution model designed to support efficient production restoration. “Building on our long collaboration in the region, this contract reflects a shared commitment to maximizing value from existing offshore resources,” said Gokhan Yarim, senior vice president of Integration, SLB. “Together with BSP, we are combining SLB’s production expertise and integrated execution capabilities to help restore production from shut-in wells, increase reco

BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries18.8.2026 12:00:00 CEST | Press release

Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028 BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively. Building on a collaboration launched in 2023, the renewed partnership reflects the organizations’ shared commitment to improving access to innovative cancer treatments in underserved communities. To date, the partnership has enabled access to BRUKINSA for more than 300 patients with CLL across Armenia, Ethiopia, and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye